Speck B, Cornu P, Sartorius J, Nissen C, Gratwohl A, Burri H P, Jeannet M
Schweiz Med Wochenschr. 1979 Dec 8;109(47):1883-5.
Experience with 17 allogeneic bone marrow transplantation (BMT) patients with refractory acute leukemia is reported. The authors show that it is extremely difficult to cure patients with end stage disease by this procedure. Based on experience that, if performed early, BMT can bring about over 50% potential cures, it is postulated that marrow grafts should be performed much earlier than is done at present. From the results in 45 patients with severe aplastic anemia it is concluded that the majority do not have a defect at the pluripotent stem cell itself. There is disturbed maturation to functional end cells which can be corrected in most instances by ALG, infusion of allogeneic marrow and low dose androgens. BMT between HLA-identical siblings need not cause major problems, but it involves a considerable risk of fatal complications such as irreversible marrow rejection and GvH.
报告了17例难治性急性白血病患者接受异基因骨髓移植(BMT)的经验。作者表明,通过该程序治愈终末期疾病的患者极其困难。基于早期进行BMT可带来超过50%潜在治愈机会的经验,推测骨髓移植应比目前的时机更早进行。从45例严重再生障碍性贫血患者的结果得出结论,大多数患者在多能干细胞本身并无缺陷。存在向功能性终末细胞的成熟障碍,在大多数情况下可通过抗淋巴细胞球蛋白、输注异基因骨髓和低剂量雄激素得到纠正。 HLA相同的同胞之间进行BMT不一定会引发重大问题,但存在诸如不可逆的骨髓排斥和移植物抗宿主病等致命并发症的相当大风险。